Advertisement

Liver Carcinoma

  • Paul J. KellyEmail author
Chapter
  • 30 Downloads

Abstract

Liver Carcinoma: this chapter outlines the incidence, risk factors, clinical presentation, investigations, treatments and prognosis of cancer at this anatomical site. These features are correlated with the core data that are required to make the corresponding histopathology reports of a consistently high quality, available in an appropriate timeframe, and clinically relevant to patient management and prognosis. Summary details of the common cancers given at this site include: gross description, histological types, tumour grade/differentiation, extent of local tumour spread, lymphovascular invasion, lymph node involvement, and the status of excision margins. Current WHO Classifications of Malignant Tumours and TNM8 are referenced. Notes are provided on other associated pathology, contemporary use of immunohistochemistry, updates on the role of evolving molecular tests, and the use of these ancillary techniques as biomarkers in diagnosis, and prediction of prognosis and treatment response. A summary is given of the more common non-carcinoma malignancies that are encountered at this site in diagnostic practice.

Keywords

Hepatocellular carcinoma Cholangiocarcinoma Hepatocellular adenoma Metastatic carcinoma Staging TNM8 

Bibliography

  1. Amin MB, Edge S, Greene F, Byrd DR, Brookland RK, Washington MK, Gershenwald JE, Compton CC, Hess KR, Sullivan DC, Jessup JM, Brierley JD, Gaspar LE, Schilsky RL, Balch CM, Winchester DP, Asare EA, Madera M, Gress DM, Meyer LR, editors. AJCC Cancer staging manual. 8th ed. Berlin: Springer International Publishing: American Joint Commission on Cancer; 2017.Google Scholar
  2. Bosman FT, Carneiro F. GI WHO classification of tumours. Digestive system tumours. 5th ed.; 2019.Google Scholar
  3. Brunt E, Aishima S, Clavien PA, Fowler K, Goodman Z, Gores G, et al. cHCC-CCA: consensus terminology for primary liver carcinomas with both hepatocytic and cholangiocytic differentation. Hepatology. 2018;68:113–26.CrossRefGoogle Scholar
  4. Burt AD, Ferrell LD, Hubscher SG. Macsween's pathology of the liver. Edinburgh: Churchill Livingstone/Elsevier; 2018.Google Scholar
  5. Di Tommaso L, Roncalli M. Tissue biomarkers in hepatocellular tumors: which, when, and how. Front Med (Lausanne). 2017:4–10.Google Scholar
  6. Forner A, Reig M, Bruix J. Hepatocellular carcinoma. Lancet. 2018;391:1301–14.Google Scholar
  7. Ishak KG, Goodman ZD, Stocker JT. Tumors of the liver and intrahepatic bile ducts. Atlas of tumor pathology. 3rd series. Fascicle 31. Washington: AFIP; 2001.Google Scholar
  8. Mounajjed T, Chandan VS, Torbenson MS. Surgical pathology of liver Tumours. Berlin: Springer; 2015.CrossRefGoogle Scholar
  9. Rastogi A. Changing role of histopathology in the diagnosis and management of hepatocellular carcinoma. World J Gastroenterol. 2018;24:4000–13.CrossRefGoogle Scholar
  10. The Royal College of Pathologists. Cancer Datasets (Oesophageal Carcinoma, Gastric Carcinoma, Carcinomas of the Pancreas, ampulla of Vater and Common Bile Duct, Colorectal Cancer, Gastrointestinal Stromal Tumours (GISTs), Liver Resection Specimens and Liver Biopsies for Primary and Metastatic Carcinoma, Endocrine Tumours of the Gastrointestinal Tract including Pancreas) and Tissue Pathways (Gastrointestinal and Pancreatobiliary Pathology, Liver Biopsies for the Investigation of Medical Disease and for Focal Liver Lesions). https://www.rcpath.org/profession/guidelines/cancer-datasets-and-tissue-pathways.html
  11. Shaker TM, Chung C, Varma MK, Doherty MG, Wolf AM, Chung MH, et al. Is there a role for Ytrrium-90 in the treatment of unresectable and metastatic intrahepatic cholangiocarcinoma? Am J Surg. 2018;215:467–70.CrossRefGoogle Scholar
  12. Valle JW, Borbath I, Khan SA, Huguet F, Gruenberger T, Arnold D, et al. Biliary cancer: ESMO clinical practice guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2016;27:v28–37.Google Scholar
  13. Vijgen S, Terris B, Rubbia-Brandt L. Pathology of intrahepatic cholangiocarcinoma. Hepatobiliary Surg Nutr. 2017;6:22–34.CrossRefGoogle Scholar
  14. Vogel A, Cervantes A, Chau I, Daniele B, Llovet J, Meyer T, et al. Hepatocellular carcinoma: ESMO clinical practice guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2018;29:iv238–iv55.Google Scholar

Copyright information

© Springer Nature Switzerland AG 2020

Authors and Affiliations

  1. 1.Institute of PathologyRoyal Victoria HospitalBelfastUK

Personalised recommendations